BioXcel Therapeutics (BTAI) Return on Sales (2022 - 2026)

BioXcel Therapeutics' Return on Sales history runs 5 years deep, the most recent figure standing at 0.67% for Q1 2026.

• In Q1 2026, Return on Sales rose 16.0% year-over-year to 0.67%; the TTM figure through Mar 2026 stood at 0.97% (down 61.0% YoY), while the FY2025 annual figure was 1.03%, down 68.0% from the prior year.
• Return on Sales was 0.67% for Q1 2026 at BioXcel Therapeutics, down from 0.56% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.18% in Q2 2024 to a low of 3.04% in Q3 2022.
• Historically, Return on Sales has averaged 1.24% across 5 years, with a median of 0.86% in 2024.
• The sharpest annual moves came in 2024 and 2025: Return on Sales jumped 207 bps in 2024, then slumped 144 bps in 2025.
• A 5-year view of Return on Sales shows it stood at 2.31% in 2022, then surged by 75 bps to 0.59% in 2023, then surged by 35 bps to 0.38% in 2024, then sank by 47 bps to 0.56% in 2025, then decreased by 19 bps to 0.67% in 2026.
• The last three Return on Sales figures came in at 0.67% (Q1 2026), 0.56% (Q4 2025), and 1.87% (Q3 2025), per Business Quant data.